Paratek Pharmaceuticals saw a 22% increase in its stock price following reports that private equity firm Gurnet Point Capital is among the potential buyers interested in acquiring the biopharmaceutical company. Paratek has marketed antibiotics Nuzyra and Seysara, and recently reported its Q1 results.
- Paratek Pharmaceuticals (NASDAQ:PRTK) soared 22% amid a report about one of the potential private equity buyers for the biopharma company.
- Gurnet Point Capital is said to be one of the PE firms circling the company, according to a Betaville “rare” alert.
- The speculation comes after Betaville said in March that Paratek (PRTK) is a takeout target and that PE firms are the likely suitors.
- Paratek’s (PRTK) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
- Paratek (PRTK) reported Q1 results last month.
Source: SeekingAlpha